Yahoo Finance

Operations: The company generates revenue of CN¥1.49 billion from its operations in China.

Market Cap: $79.27M

So-Young International Inc., with a market cap of $79.27 million, reported third-quarter revenue of CN¥371.83 million and net income of CN¥20.35 million, reflecting modest earnings growth compared to the previous year. Despite its volatile share price and recent shareholder dilution, the company maintains a strong balance sheet with more cash than total debt and short-term assets exceeding liabilities significantly. While earnings have grown slightly over the past year, they still lag behind long-term averages; however, forecasts suggest accelerated growth ahead. The company's low return on equity indicates room for improvement in profitability metrics despite high-quality earnings reports.

• Click here to discover the nuances of So-Young International with our detailed analytical financial health report.

• Learn about So-Young International's future growth trajectory here.

OraSure Technologies

Simply Wall St Financial Health Rating: ★★★★★★

Overview: OraSure Technologies, Inc. operates in the United States, Europe, and internationally by providing point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services with a market cap of approximately $291.66 million.

Operations: The company's revenue primarily comes from its Diagnostics and Molecular Solutions segment, which generated $224.26 million.

Market Cap: $291.66M

OraSure Technologies, Inc., with a market cap of approximately US$291.66 million, operates in the diagnostics sector with significant revenue from its Diagnostics and Molecular Solutions segment. Despite being debt-free and having short-term assets of US$350.2 million exceeding liabilities, the company faces challenges with declining profit margins (5.1% from 10.9%) and negative earnings growth (-77%). Recent financials show a third-quarter revenue drop to US$39.92 million from US$89.19 million year-on-year, resulting in a net loss of US$4.51 million compared to previous profits. The company recently secured federal funding for developing a Marburg Virus Disease test, continuing its collaboration with BARDA for diagnostic advancements.

• Take a closer look at OraSure Technologies' potential here in our financial health report.

• Examine OraSure Technologies' earnings growth report to understand how analysts expect it to perform.

Make It Happen

• Explore the 701 names from our US Penny Stocks screener here.

• Are any of these part of your asset mix? Tap into the analytical power of Simply Wall St's portfolio to get a 360-degree view on how they're shaping up.

• Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent.

Searching for a Fresh Perspective?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.

• Jump on the AI train with fast growing tech companies forging a new era of innovation.

• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include NasdaqCM:CRGO NasdaqGM:SY and NasdaqGS:OSUR.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com